Emerging analgesics and future directions: Targeting neuroplasticity

Alysia N. Lozano-Ondoua, Todd W Vanderah

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Quality of life is defined as an individual's perception of their culture and values, as well as their goals, morals and concerns [1]. Pain induced by progression of disease and adverse events associated with standard therapies significantly diminishes the quality of life in cancer patients [1,2]. Recent findings with a BRAF inhibitor in advanced stages of melanoma have emphasized the need for treatments to reduce pain and increase survival time in terminally ill cancer patients [3]. Reports highlighted the importance in patient quality of life in late stages of cancer and how family and physicians surrounding the patient may be affected [3]. Current therapies for advanced stages of cancer pain include opioids and bisphosphonates. Recent studies have demonstrated that sustained morphine not only intensifies tumor-induced pain but also accelerates tumor-induced bone destruction in a murine bone cancer model [4]. In addition, chronic use of opioids results in several unbearable side effects, including analgesic tolerance, constipation, respiratory depression and somnolence [5]. Bisphosphonates lack analgesic efficacy and entail adverse events, including osteonecrosis of the jaw and disruption of normal serum calcium levels [6]. Although advances in cancer therapeutics have increased survival times of cancer patients, including those with metastases, treatment in advanced stages of cancer and palliative care has not improved. Thus, there is a great need for novel therapeutics that not only have antitumor effects, but attenuate the pain and/or limit the side effects seen with current patient care.

Original languageEnglish (US)
Title of host publicationAnalgesics for Cancer Pain
PublisherFuture Medicine Ltd.
Pages95-101
Number of pages7
ISBN (Print)9781780840741, 9781780841373
DOIs
StatePublished - Feb 1 2012

Fingerprint

Neuronal Plasticity
Analgesics
Neoplasms
Pain
Quality of Life
Diphosphonates
Opioid Analgesics
Therapeutics
Terminally Ill
Bone Neoplasms
Osteonecrosis
Survival
Direction compound
Family Physicians
Constipation
Jaw
Palliative Care
Respiratory Insufficiency
Morphine
Disease Progression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lozano-Ondoua, A. N., & Vanderah, T. W. (2012). Emerging analgesics and future directions: Targeting neuroplasticity. In Analgesics for Cancer Pain (pp. 95-101). Future Medicine Ltd.. https://doi.org/10.2217/EBO.11.377

Emerging analgesics and future directions : Targeting neuroplasticity. / Lozano-Ondoua, Alysia N.; Vanderah, Todd W.

Analgesics for Cancer Pain. Future Medicine Ltd., 2012. p. 95-101.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lozano-Ondoua, AN & Vanderah, TW 2012, Emerging analgesics and future directions: Targeting neuroplasticity. in Analgesics for Cancer Pain. Future Medicine Ltd., pp. 95-101. https://doi.org/10.2217/EBO.11.377
Lozano-Ondoua AN, Vanderah TW. Emerging analgesics and future directions: Targeting neuroplasticity. In Analgesics for Cancer Pain. Future Medicine Ltd. 2012. p. 95-101 https://doi.org/10.2217/EBO.11.377
Lozano-Ondoua, Alysia N. ; Vanderah, Todd W. / Emerging analgesics and future directions : Targeting neuroplasticity. Analgesics for Cancer Pain. Future Medicine Ltd., 2012. pp. 95-101
@inbook{af501fb546d148deb2ec259d5e1a5ed9,
title = "Emerging analgesics and future directions: Targeting neuroplasticity",
abstract = "Quality of life is defined as an individual's perception of their culture and values, as well as their goals, morals and concerns [1]. Pain induced by progression of disease and adverse events associated with standard therapies significantly diminishes the quality of life in cancer patients [1,2]. Recent findings with a BRAF inhibitor in advanced stages of melanoma have emphasized the need for treatments to reduce pain and increase survival time in terminally ill cancer patients [3]. Reports highlighted the importance in patient quality of life in late stages of cancer and how family and physicians surrounding the patient may be affected [3]. Current therapies for advanced stages of cancer pain include opioids and bisphosphonates. Recent studies have demonstrated that sustained morphine not only intensifies tumor-induced pain but also accelerates tumor-induced bone destruction in a murine bone cancer model [4]. In addition, chronic use of opioids results in several unbearable side effects, including analgesic tolerance, constipation, respiratory depression and somnolence [5]. Bisphosphonates lack analgesic efficacy and entail adverse events, including osteonecrosis of the jaw and disruption of normal serum calcium levels [6]. Although advances in cancer therapeutics have increased survival times of cancer patients, including those with metastases, treatment in advanced stages of cancer and palliative care has not improved. Thus, there is a great need for novel therapeutics that not only have antitumor effects, but attenuate the pain and/or limit the side effects seen with current patient care.",
author = "Lozano-Ondoua, {Alysia N.} and Vanderah, {Todd W}",
year = "2012",
month = "2",
day = "1",
doi = "10.2217/EBO.11.377",
language = "English (US)",
isbn = "9781780840741",
pages = "95--101",
booktitle = "Analgesics for Cancer Pain",
publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - Emerging analgesics and future directions

T2 - Targeting neuroplasticity

AU - Lozano-Ondoua, Alysia N.

AU - Vanderah, Todd W

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Quality of life is defined as an individual's perception of their culture and values, as well as their goals, morals and concerns [1]. Pain induced by progression of disease and adverse events associated with standard therapies significantly diminishes the quality of life in cancer patients [1,2]. Recent findings with a BRAF inhibitor in advanced stages of melanoma have emphasized the need for treatments to reduce pain and increase survival time in terminally ill cancer patients [3]. Reports highlighted the importance in patient quality of life in late stages of cancer and how family and physicians surrounding the patient may be affected [3]. Current therapies for advanced stages of cancer pain include opioids and bisphosphonates. Recent studies have demonstrated that sustained morphine not only intensifies tumor-induced pain but also accelerates tumor-induced bone destruction in a murine bone cancer model [4]. In addition, chronic use of opioids results in several unbearable side effects, including analgesic tolerance, constipation, respiratory depression and somnolence [5]. Bisphosphonates lack analgesic efficacy and entail adverse events, including osteonecrosis of the jaw and disruption of normal serum calcium levels [6]. Although advances in cancer therapeutics have increased survival times of cancer patients, including those with metastases, treatment in advanced stages of cancer and palliative care has not improved. Thus, there is a great need for novel therapeutics that not only have antitumor effects, but attenuate the pain and/or limit the side effects seen with current patient care.

AB - Quality of life is defined as an individual's perception of their culture and values, as well as their goals, morals and concerns [1]. Pain induced by progression of disease and adverse events associated with standard therapies significantly diminishes the quality of life in cancer patients [1,2]. Recent findings with a BRAF inhibitor in advanced stages of melanoma have emphasized the need for treatments to reduce pain and increase survival time in terminally ill cancer patients [3]. Reports highlighted the importance in patient quality of life in late stages of cancer and how family and physicians surrounding the patient may be affected [3]. Current therapies for advanced stages of cancer pain include opioids and bisphosphonates. Recent studies have demonstrated that sustained morphine not only intensifies tumor-induced pain but also accelerates tumor-induced bone destruction in a murine bone cancer model [4]. In addition, chronic use of opioids results in several unbearable side effects, including analgesic tolerance, constipation, respiratory depression and somnolence [5]. Bisphosphonates lack analgesic efficacy and entail adverse events, including osteonecrosis of the jaw and disruption of normal serum calcium levels [6]. Although advances in cancer therapeutics have increased survival times of cancer patients, including those with metastases, treatment in advanced stages of cancer and palliative care has not improved. Thus, there is a great need for novel therapeutics that not only have antitumor effects, but attenuate the pain and/or limit the side effects seen with current patient care.

UR - http://www.scopus.com/inward/record.url?scp=84959090313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959090313&partnerID=8YFLogxK

U2 - 10.2217/EBO.11.377

DO - 10.2217/EBO.11.377

M3 - Chapter

AN - SCOPUS:84959090313

SN - 9781780840741

SN - 9781780841373

SP - 95

EP - 101

BT - Analgesics for Cancer Pain

PB - Future Medicine Ltd.

ER -